Norouzinia Mohsen, Chaleshi Vahid, Alinaghi Samaneh, Beheshti Shirazi Saeedeh Sadat, Keramatinia Aliasghar, Nourian Mahyar
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2018 Winter;11(Suppl 1):S45-S52.
Aim of this study was to compare the gene expression of Interleukin 12 members in two phase of IBD.
Inflammatory bowel disease (IBD) is a well-known gastrointestinal disorder in the world that fluctuates between remission and flare-up phases. Each of these phases has an individual immune system response profile. Therefore, analyzing the interleukins (IL) expression status improves the diagnosis and the classification of the IBD cases.
In this a case-control study, among 400 patients whom admitted to the IBD clinic, forty nine IBD patients were included. Patients were divided into three categories based on 1) the phase of the disease, 2) the type of IBD, Ulcerative colitis (UC) or Crohn's disease (CD), and 3) the therapeutic pathways. Using the real-time PCR method, the expression levels of IL-12A, IL-12B, IL-23A, and IL-27 were examined in the peripheral blood mononuclear cell (PBMC) and compared to the pre-described subgroups.
the data showed upregulation in the expression levels of IL-12A and IL-12B in the remission phase in comparison with the flare-up. However, no significant changes were obtained from the evaluation of IL-23A and IL-27. In addition, the mRNA levels of the target genes in the subgroups of Category 2 as well as Category 3 were similar.
Our results showed that expression patterns of the IL-12A and IL-12B genes varied between the remission and flare-up phases for the IBD patients, and may be considered as potential biomarkers for the detection and the classification of IBD cases.
本研究旨在比较炎症性肠病两个阶段白细胞介素12成员的基因表达。
炎症性肠病（IBD）是一种世界范围内广为人知的胃肠道疾病，在缓解期和发作期之间波动。每个阶段都有各自的免疫系统反应特征。因此，分析白细胞介素（IL）的表达状态有助于改善IBD病例的诊断和分类。
在这项病例对照研究中，纳入了400名入住IBD诊所的患者中的49名IBD患者。患者根据以下因素分为三类：1）疾病阶段；2）IBD类型，溃疡性结肠炎（UC）或克罗恩病（CD）；3）治疗途径。采用实时PCR方法，检测外周血单个核细胞（PBMC）中IL-12A, IL-12B, IL-23A和IL-27的表达水平，并与预先设定的亚组进行比较。
数据显示，与发作期相比，缓解期IL-12A和IL-12B的表达水平上调。然而，IL-23A和IL-27的评估结果无显著变化。此外，第2类和第3类亚组中靶基因的mRNA水平相似。
我们的结果表明，IBD患者缓解期和发作期之间IL-12A和IL-12B基因的表达模式不同，可被视为检测和分类IBD病例的潜在生物标志物。
